FDA
-
-
-
-
-
-
-
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
-
-
-
-
-
-
-
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
-
-
-
-
-
-
-
Arcutis publishes long-term ZORYVE safety data for pediatric atopic dermatitis
-
-
-
-
-
-
-
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
-
-
-
-
-
-
-
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
-
-
-
-
-
-
-
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Arcutis submits application to expand ZORYVE for children ages 2-5
-
328,143 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

